<div id="readability-page-1"><p>Assenagon Asset Management S.A. lessened its stake in  Emergent Biosolutions Inc. (NYSE:EBS - Free Report) by 81.8% in the third quarter, according to the company in its most recent disclosure with the Securities &amp; Exchange Commission. The institutional investor  owned 56,455 shares of the biopharmaceutical company's stock after selling 253,236 shares during the quarter. Assenagon Asset Management S.A. owned about 0.11% of Emergent Biosolutions worth $498,000 at the end of the most recent reporting period.</p><div><p><span></span><span>Get <strong>Emergent Biosolutions</strong> alerts:</span></p></div><ul><li>3 Small-Cap Stocks to Watch After the Fed’s Rate Cuts</li></ul><p>Several other institutional investors and hedge funds have also bought and sold shares of EBS. Vanguard Personalized Indexing Management LLC increased its holdings in shares of  Emergent Biosolutions by 14.1% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 17,824 shares of the biopharmaceutical company's stock worth $114,000 after buying an additional 2,204 shares in the last quarter.  Cetera Investment Advisers grew its position in  Emergent Biosolutions by 0.7% during the 2nd quarter. Cetera Investment Advisers now owns 358,952 shares of the biopharmaceutical company's stock worth $2,290,000 after acquiring an additional 2,671 shares during the last quarter.  EP Wealth Advisors LLC grew its position in  Emergent Biosolutions by 33.1% during the 1st quarter. EP Wealth Advisors LLC now owns 15,249 shares of the biopharmaceutical company's stock worth $74,000 after acquiring an additional 3,790 shares during the last quarter.  Legal &amp; General Group Plc acquired a new position in  Emergent Biosolutions in the 2nd quarter worth about $31,000.  Finally, Ameritas Investment Partners Inc. bought a new position in  Emergent Biosolutions in the second quarter valued at about $35,000. Institutional investors own  78.40% of the company's stock. </p><h2>Emergent Biosolutions Stock Performance</h2><p>EBS stock opened at $12.63 on Friday. Emergent Biosolutions Inc. has a 1 year low of $4.02 and a 1 year high of $13.41. The company has a market cap of $663.33 million, a P/E ratio of 9.72 and a beta of 2.32. The company has a debt-to-equity ratio of 1.14, a current ratio of 5.76 and a quick ratio of 3.15. The stock's fifty day moving average price is $10.94 and its 200-day moving average price is $8.86. </p><ul><li>Big Rallies Brewing? 3 Analyst Favorites to Watch Closely</li></ul><p>Emergent Biosolutions (NYSE:EBS - Get Free Report) last issued its quarterly earnings data on Tuesday, January 9th. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter. Emergent Biosolutions had a net margin of 9.62% and a return on equity of 20.85%. The business had revenue of $222.50 million for the quarter.  On average, equities analysts forecast that  Emergent Biosolutions Inc. will post -0.63 earnings per share for the current year. </p><h2>Insider Transactions at Emergent Biosolutions</h2><p>In related news, Director Ronald Richard sold 21,984 shares of the stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $11.97, for a total transaction of $263,148.48. Following the completion of the transaction, the director directly owned 98,417 shares of the company's stock, valued at approximately $1,178,051.49. This represents a 18.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this link. Also, EVP Coleen Glessner sold 30,608 shares of Emergent Biosolutions stock in a transaction that occurred on Tuesday, October 7th. The stock was sold at an average price of $10.00, for a total value of $306,080.00. Following the completion of the sale, the executive vice president directly owned 144,319 shares in the company, valued at approximately $1,443,190. The trade was a 17.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 1.20% of the stock is owned by company insiders. </p><h2>Wall Street Analysts Forecast Growth</h2><ul><li>Watch These 4 Overbought Stocks As Market Rotation Continues</li></ul><p>A number of research analysts recently issued reports on the stock. Zacks Research upgraded shares of Emergent Biosolutions to a &#34;hold&#34; rating in a research report on Friday, October 24th. HC Wainwright  reaffirmed a &#34;buy&#34; rating and set a $15.00 price target on shares of Emergent Biosolutions in a research note on Tuesday, December 16th. Weiss Ratings  reissued a &#34;hold (c-)&#34; rating on shares of Emergent Biosolutions in a research note on Monday. Finally, Wall Street Zen raised Emergent Biosolutions from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report on Sunday, November 30th. One research analyst  has rated the stock with a Buy rating and two have issued  a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of &#34;Hold&#34; and an average target price of $15.00.</p><p><b>Check Out Our Latest Report on EBS</b></p><h2>About Emergent Biosolutions</h2> (Free Report)<p>Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company's portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.  </p><p>Key commercial products in Emergent's lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Emergent Biosolutions</li><li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li><li>Turn your &#34;dead money&#34; into $306+ monthly (starting this month)</li><li>Washington prepares for war</li><li>Strange Crystal Metal Outperforms Silicon Up to 100X</li><li>33,000% boom from weird new “AI Fuel?”</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVCUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVCUw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Emergent Biosolutions Right Now?</h2><p>Before you consider Emergent Biosolutions, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Emergent Biosolutions wasn't on the list.</p><p>While Emergent Biosolutions currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Assenagon Asset Management S.A. reduced its stake in Emergent Biosolutions Inc. by 81.8% in Q3, now holding 56,455 shares worth $498,000. Other institutional investors, including Vanguard and Cetera, adjusted their positions in EBS. Emergent Biosolutions' stock opened at $12.63, with a market cap of $663.33 million. Analysts have mixed ratings on the stock, with some upgrading it to "strong-buy."</p>

Assenagon Asset Management S.A. Has $498,000 Stock Position in Emergent Biosolutions Inc. $EBS